Keywords: Genzyme, Renvela, PPB, Kidney disease, Research

Genzyme’s woes continue as it drops investigational APB follow-up for Renvela, after poor trial results

Article | 19 November 2009

US biotechnology major Genzyme has reported results of a Phase II/III study of its advanced phosphate binder (APB), a stronger version of its already-marketed kidney disease drug Renvela (sevelamer carbonate), which met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo in patients with chronic kidney disease. However, the APB did not show a significant improvement in phosphate lowering compared to Renvela.

Based on these results, the company is not planning to pursue further clinical development of the new APB. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in